文献速递治疗药物监测与药物基因组学

年龄与BMI对贝叶斯软件中万古霉素模型选择的影响:大型多中心回顾性研究

Impacts of age and BMI on vancomycin model choice in a Bayesian software: Lessons from a very large multi-site retrospective study.
PubMed 文献 · Pharmacotherapy · 2024-10-09

BACKGROUND: Model-informed precision dosing (MIPD) optimizes drug doses based on pharmacokinetic (PK) model predictions, necessitating careful selection of models tailored to patient characteristics.…

要点

  • 年龄和BMI影响万古霉素药动学模型的预测准确性,需个体化选择模型。
  • 年轻成人(18-64岁)中模型预测性能普遍低于老年人,提示需改进模型。
  • 先验预测时,Colin模型在多数BMI类别的18-64岁成人中表现最佳。

核心结论

  • 不同年龄-BMI亚组应选择特定的万古霉素药动学模型以优化贝叶斯精准给药。
  • 年轻成人患者的模型预测性能较差,需要改进模型。

主要发现

  • 模型准确性在不同年龄-BMI类别间为41%-73%,获得TDM进行贝叶斯估计后准确性提高。
  • 年轻成人模型表现差于老年人,最优模型随年龄-BMI类别和预测方法变化。
  • 先验预测期,Colin模型在18-64岁多数BMI类别中最佳,Goti/Tong模型在老年非肥胖成人中最佳,Hughes模型在多数肥胖类别中最佳。

关键数值与推荐

  • 模型筛选标准:平均百分比误差(MPE)≤20%且归一化均方根误差(RMSE)<8 mg/L,再从中选择最准确模型。

临床怎么用

  • 临床使用贝叶斯精准给药软件时,应根据患者年龄和BMI选择相应最优模型。
  • 对年轻成人患者,需警惕模型预测偏差,加强TDM监测。

局限性

  • 回顾性研究设计可能引入偏倚。
  • 研究仅使用InsightRX数据库,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Model-informed precision dosing (MIPD) optimizes drug doses based on pharmacokinetic (PK) model predictions, necessitating careful selection of models tailored to patient characteristics. This study evaluates the predictive performance of various vancomycin PK models across diverse age and BMI categories, drawing insights from a large multi-site database. METHODS: Adults receiving vancomycin intravenous therapy at United States health systems between January 1, 2022, and December 31, 2023, were included. Patient demographics, vancomycin administration records, and therapeutic drug monitoring levels (TDMs) were collected from the InsightRX database. Age and body mass index (BMI)-based subgroups were formed to assess model performance, with predictions made iteratively. The optimal model for each age-BMI subgroup was chosen based on predefined criteria: models were filtered for mean percentage error (MPE) ≤ 20% and normalized root mean squared error (RMSE) < 8 mg/L, and then the most accurate among them was selected. RESULTS: A total of 384,876 treatment courses across 155 US health systems were analyzed, contributing 841,604 TDMs. Eleven models were compared, showing varying accuracy across age-BMI categories (41%-73%), with higher accuracy observed once TDMs were available for Bayesian estimates of individual PK parameters. Models performed more poorly in younger adults compared to older adults, and the optimal model differed depending on age-BMI categories and prediction methods. Notably, in the a priori period, the Colin model performed best in adults aged 18-64 years across most BMI categories; the Goti/Tong model performed best in the older, non-obese adults; and the Hughes model performed best in many of the obese categories. CONCLUSION: Our study identifies specific vancomycin PK models that demonstrate superior predictions across age-BMI categories in MIPD applications. Our findings underscore the importance of tailored model selection for vancomycin management, especially highlighting the need for improved models in younger adult patients. Further research into the clinical implications of model performance is warranted to enhance patient care outcomes.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Hughes MA, Lee T, Faldasz JD, et al. Impacts of age and BMI on vancomycin model choice in a Bayesian software: Lessons from a very large multi-site retrospective study. Pharmacotherapy. 2024. PMID: 39382218. doi:10.1002/phar.4613

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。